Evaluation of Antitumor Activity Using Change in Tumor Size of the Survivin Antisense Oligonucleotide LY2181308 in Combination with Docetaxel for Second-Line Treatment of Patients with Non–Small-Cell Lung Cancer: A Randomized Open-Label Phase II Study

Autor: Natale, Ronald, Blackhall, Fiona, Kowalski, Dariusz, Ramlau, Rodryg, Bepler, Gerold, Grossi, Francesco, Lerchenmüller, Christian, Pinder-Schenck, Mary, Mezger, Jörg, Danson, Sarah, Gadgeel, Shirish M., Summers, Yvonne, Callies, Sophie, André, Valérie, Das, Mayukh, Lahn, Michael, Talbot, Denis
Zdroj: In Journal of Thoracic Oncology November 2014 9(11):1704-1708
Databáze: ScienceDirect